Human Vaccines Market Expected to Witness a CAGR of 11.20% through 2016 - 2024

The global human vaccines market is predominantly consolidated, states Transparency Market Research (TMR) in a new research study. The top players in this market are Pfizer Inc., Sanofi, GlaxoSmithKline plc, and Merck & Co. Inc. Collectively, these four players accounted for 70% of the overall market in 2015. Researchers at TMR expect this scenario to remain more or less the same over the next few years, though these participants will try to overshadow each other by using various strategies, such as product differentiation and tactical partnerships, notes the market study.

According to the research report, the global market for human vaccines presented an opportunity worth US$28.3 bn in 2015. Progressing at a sturdy CAGR of 11.20% during the period from 2016 to 2024, the market is expected to touch US$72.5 bn by the end of the forecast period. The demand for conjugate vaccines is relatively higher than other vaccine types at present. However, combination vaccines are expected to create more lucrative opportunities in the years to come, thanks to the rising preference for commercial brands.

Request for Sample Copy of Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=16127

Currently, hospitals have surfaced as the most prominent distribution channels for human vaccines. Although the scenario will remain almost similar over the next few years, drugstores are anticipated to demonstrate a promising growth rate, thanks to a significantly rising vaccination rate in standalone pharmacies in developed economies. Among the regional markets, North America is anticipated to continue dominating the global market over the forthcoming years, states the research report.

Rising Awareness about Benefits of Vaccines to Boost Demand

“The global market for human vaccines is observing tremendous growth, thanks to the increasing awareness about the advantages of vaccines over other modes of drug administrations,” says the author of this report. As vaccines demonstrate a significantly low risk of serious side-effects when compared to other methods of drug administration, their demand is relatively higher at present and is expected to continue increasing in the years to come.

Request for TOC @ https://www.transparencymarketresearch.com/report-toc/16127

Apart from this, the increasing number of awareness programs by various governments and private and not-for-profit organizations is also projected to support the growth of this market over the next few years, reports the research study.

Stringent Regulatory Requirements to Pose A Threat to Market’s Growth

The future of the worldwide market for human vaccines looks bright. However, the presence of stringent regulatory requirements is likely to create hurdles in the otherwise smooth growth of this market in the years to come. Besides, the high cost of these vaccines, together with their handling, storage, and transportation, is also expected to pose a challenge to this market over the forthcoming years, states the market report.

Obtain Report Details @ https://www.transparencymarketresearch.com/human-vaccines-market.html

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Contact Us

Transparency Market Research
State Tower,
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.